← Leaderboards
Youngjae You
University Of Oklahoma Hlth Sciences Ctr
$4,324,163
Attributed
$4,324,163
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $763.8K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,324,163 · 2
By mechanism
R01$4,324,163 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Robert Evan Hurst$6,096,126
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsMalignant NeoplasmsChemotherapyPharmaceutical PreparationsPuva PhotochemotherapyPhysiologicalSinglet OxygenCellsLightTumorDiagnosisMalignant Neoplasm Of OvaryProdrugsRegimenOperative Surgical ProceduresCessation Of LifeOpticsCancer CellCancer PatientFda ApprovedIn VitroDiffusionAntineoplastic AgentsNormal Tissue Morphology
Grant awards (15)
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers$420,554
R01 · FY2025 · CA · contact PI
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation$343,252
R01 · FY2025 · GM · contact PI
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers$399,528
R01 · FY2024 · CA · contact PI
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation$343,252
R01 · FY2024 · GM · contact PI
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers$411,292
R01 · FY2023 · CA · contact PI
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation$342,275
R01 · FY2023 · GM · contact PI
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers$433,815
R01 · FY2022 · CA · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$164,088
R01 · FY2019 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$147,604
R01 · FY2019 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$303,400
R01 · FY2018 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$303,400
R01 · FY2017 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$194,804
R01 · FY2016 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$128,900
R01 · FY2016 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$108,595
R01 · FY2016 · GM · contact PI
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers$279,404
R01 · FY2015 · GM · contact PI